Is VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) suited for growth investing?

Groth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) is suited for growth investing. Investors should of course do their own research, but we spotted VOYAGER THERAPEUTICS INC showing up in our CANSLIM growth screen, so it may be worth spending some more time on it.

What matters for canslim investors.

• VOYAGER THERAPEUTICS INC has demonstrated consistent growth in its earnings per share (EPS) from one quarter to another (Q2Q), with a 305.0% increase. This indicates improving financial performance and the company's effective management of its operations.
• VOYAGER THERAPEUTICS INC has experienced 6.0K% q2q revenue growth, indicating a significant sales increase.
• Over the past 3 years, VOYAGER THERAPEUTICS INC has demonstrated 48.16% growth in EPS, signifying its positive financial trajectory and potential for future profitability.
• VOYAGER THERAPEUTICS INC exhibits a strong Return on Equity (ROE) of 55.98%, indicating the company's ability to generate solid returns on shareholder investments. This metric reflects the company's efficient utilization of equity capital and its profitability.
• VOYAGER THERAPEUTICS INC has exhibited strong Relative Strength(RS) in recent periods, with a current 83.87 rating. This indicates the stock's ability to outperform the broader market and reflects its competitive position. VOYAGER THERAPEUTICS INC shows promising potential for continued price momentum.
• Maintaining a Debt-to-Equity ratio of 0.0, VOYAGER THERAPEUTICS INC demonstrates a conservative financial approach. This signifies the company's focus on minimizing debt burdens while preserving a solid equity position.
• With institutional shareholders at 47.6%, VOYAGER THERAPEUTICS INC demonstrates a healthy ownership distribution. This reflects a mix of institutional and individual investors, creating a market environment that may foster increased trading activity and price discovery.

In-Depth Technical Analysis of NASDAQ:VYGR

ChartMill assigns a Technical Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple technical indicators and properties.

We assign a technical rating of 9 out of 10 to VYGR. Both in the recent history as in the last year, VYGR has proven to be a steady performer, scoring decent points in every aspect analyzed.

• The long and short term trends are both positive. This is looking good!
• Looking at the yearly performance, VYGR did better than 83% of all other stocks. However, this overall performance is mostly based on the strong move around 10 months ago.
• VYGR is an average performer in the Biotechnology industry, it outperforms 65% of 598 stocks in the same industry.
• VYGR is currently trading in the middle of its 52 week range. The S&P500 Index however is currently trading near new highs, so VYGR is lagging the market.
• In the last month VYGR has a been trading in the 7.08 - 10.63 range, which is quite wide. It is currently trading in the middle of this range, so some resistance may be found above.

Check the latest full technical report of VYGR for a complete technical analysis.

Fundamental analysis of NASDAQ:VYGR

As part of its analysis, ChartMill provides a comprehensive Fundamental Rating for each stock. This rating, ranging from 0 to 10, is updated on a daily basis and is based on the evaluation of various fundamental indicators and properties.

Taking everything into account, VYGR scores 6 out of 10 in our fundamental rating. VYGR was compared to 598 industry peers in the Biotechnology industry. VYGR is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VYGR has a correct valuation and a medium growth rate.

For an up to date full fundamental analysis you can check the fundamental report of VYGR

More growth stocks can be found in our CANSLIM screen.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.